Products
Lofacimig Biosimilar Biparatopic Antibody (Factor XI) for Research
Cat No.: GMP-Bios-INN-1264
Anti-F11 therapeutic antibody (Pre-made Lofacimig biosimilar,Bispecific Tandem VH Domains fused to G1 Constant Domain) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Lofacimig (development code KN-060) is a bispecific antibody targeting coagulation factor XI (F11). It is developed for thrombosis. Further development details are under investigation.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1264-1mg | 1mg | |
| GMP-Bios-INN-1264-10mg | 10mg | |
| GMP-Bios-INN-1264-100mg | 100mg | |
| GMP-Bios-INN-1264-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Lofacimig biosimilar, Bispecific Tandem VH Domains fused to G1 Constant Domain, Anti-F11;F11 Antibody: Anti-F11/Coagulation factor XI/FXI/Plasma thromboplastin antecedent (PTA) therapeutic antibody |
| INN Name | Lofacimig |
| Target | F11;F11 |
| Format | Bispecific Tandem VH Domains fused to G1 Constant Domain |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | na |
| Highest_Clin_Trial (Jan '20) | TBC |
| Est. Status | Active |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2024 |
| Year Recommended | na |
| Companies | TBC |
| Conditions Approved | TBC |
| Conditions Active | TBC |
| Conditions Discontinued | TBC |
| Production | na |
| Development Tech | TBC |
